A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

• Published in: Curēus (Palo Alto, CA) Vol. 13; no. 9; p. e18221
• Main Authors: Singh, Bishnu Mohan, Bohara, Narayan, Gautam, Kamal, Basnet, Madan, Kc, Sistu, Kc, Binod, Raut, Anuradha, Phudong, Abisha, Gautam, Jeevan
• Format: Journal Article
• Language: English
• Published: United States Cureus 23.09.2021
• Subjects: Cardiac/Thoracic/Vascular Surgery; Cardiology; Internal Medicine; heart failure; amyloid; outcomes; echocardiography; cardiac biomarkers; ttr-stabilizing drug; cardiomyopathies; tafamidis; randomized controlled trial; transthyretin amyloid cardiomyopathy
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.18221

Transthyretin amyloid cardiomyopathy disease burden is increasing daily due to advancements in diagnostic and imaging modalities in the modern world. Tafamidis is one of many therapeutic options. The main objective of this review is to study the role of Tafamidis in slowing the progression of transthyretin cardiomyopathy (TTR-CM) by analyzing randomized controlled trials (RCTs) and non-RCTs of Tafamidis. We searched for published papers of Tafamidis in the English language in electronic databases like Google Scholar, PubMed, Cochrane Library, and PubMed Central. We imported the resulting articles from our search to Mendeley software. Four reviewers removed the duplicates and performed title and abstract screening of the articles. The same reviewers obtained the full-text of relevant articles and did full-text screening based on eligibility criteria. Finally, five reviewers performed a quality assessment of RCTs using the Cochrane risk of bias assessment and of non-RCTs by a checklist prepared by Downs and Black. Any disagreements about any process were resolved by a discussion with other authors. One RCT and five non-RCTs of Tafamidis were included in this systematic review. From the non-RCTs, stability was observed in different parameters like echocardiographic findings, cardiac biomarkers, and ECG in patients with transthyretin cardiomyopathy during the study duration with Tafamidis. ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) trial demonstrated reduction of cardiovascular events and all-cause mortality in the Tafamidis group in comparison to placebo. In both RCT and non-RCTs, Tafamidis was established as a safe and tolerable drug for patients with TTR-CM. Our study proved the role of Tafamidis in reducing cardiovascular events, all-cause mortality, and the progression of cardiac disease in TTR-CM patients. In addition to five non-RCTs, current evidence is based on the findings of only one RCT of Tafamidis. Hence, evidence from additional RCTs is required to strongly support the stability of parameters like echocardiographic findings, cardiac biomarkers, and ECG with Tafamidis use.